Loading…
Based on limited metadata, Riverstone LLC, a drug manufacturer or distributor, received an FDA Warning Letter on December 21, 2020, indicating significant regulatory compliance concerns. While the specific violations cannot be detailed without access to the full letter text, the warning falls under FDA drug product regulations and enforcement. The letter's issuance suggests the company failed to meet federal requirements for drug manufacturing, labeling, quality control, or distribution practices. Additional details regarding the specific violations and required corrective actions would be available in the complete Warning Letter documentation.